

Atsuya Takeda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8531358/publications.pdf>

Version: 2024-02-01

61
papers

3,674
citations

185998

28
h-index

143772

57
g-index

62
all docs

62
docs citations

62
times ranked

3250
citing authors

#	ARTICLE	IF	CITATIONS
1	Feasibility of marker-less stereotactic body radiotherapy for hepatocellular carcinoma. <i>Acta Oncologica</i> , 2022, 61, 104-110.	0.8	4
2	Impact of Local Recurrence on Cause-Specific Death After Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer: Dynamic Prediction Using Landmark Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1135-1143.	0.4	3
3	In Regard to Chang et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 574.	0.4	0
4	CT Findings and Treatment Outcomes of Ground-Glass Opacity Predominant Lung Cancer After Stereotactic Body Radiotherapy. <i>Clinical Lung Cancer</i> , 2022, 23, 428-437.	1.1	3
5	Pathological Appearance of Focal Liver Reactions after Radiotherapy for Hepatocellular Carcinoma. <i>Diagnostics</i> , 2022, 12, 1072.	1.3	2
6	Applying Artificial Neural Networks to Develop a Decision Support Tool for Tisâ€“4NOM0 Nonâ€“Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy. <i>JCO Clinical Cancer Informatics</i> , 2022, , .	1.0	0
7	Multicenter prospective study of stereotactic body radiotherapy for previously untreated solitary primary hepatocellular carcinoma: The STRSPH study. <i>Hepatology Research</i> , 2021, 51, 461-471.	1.8	40
8	Hypofractionated radiotherapy for hepatocellular carcinomas adjacent to the gastrointestinal tract. <i>Hepatology Research</i> , 2021, 51, 294-302.	1.8	7
9	Safety and efficacy study: Short-term application of radiofrequency ablation and stereotactic body radiotherapy for Barcelona Clinical Liver Cancer stage 0â€“B1 hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0245076.	1.1	2
10	Use of Contrast-Enhanced Ultrasound with Sonazoid for Evaluating the Radiotherapy Efficacy for Hepatocellular Carcinoma. <i>Diagnostics</i> , 2021, 11, 486.	1.3	5
11	Comparison of stereotactic body radiotherapy and radiofrequency ablation for hepatocellular carcinoma: Systematic review and metaâ€“analysis of propensity score studies. <i>Hepatology Research</i> , 2021, 51, 813-822.	1.8	13
12	Effects of sample size and data augmentation on U-Net-based automatic segmentation of various organs. <i>Radiological Physics and Technology</i> , 2021, 14, 318-327.	1.0	12
13	Stereotactic Body Radiation Therapy With a High Maximum Dose Improves Local Control, Cancer-Specific Death, and Overall Survival in Peripheral Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 143-151.	0.4	25
14	Development and validation of a prognostic model for non-lung cancer death in elderly patients treated with stereotactic body radiotherapy for non-small cell lung cancer. <i>Journal of Radiation Research</i> , 2021, , .	0.8	4
15	Three Cases of Hepatocellular Carcinoma With Massive Macrovascular Invasion Successfully Treated With Radiotherapy. <i>Cureus</i> , 2021, 13, e18624.	0.2	0
16	Optimal application of stereotactic body radiotherapy and radiofrequency ablation treatment for different multifocal hepatocellular carcinoma lesions in patients with Barcelona Clinic Liver Cancer stage A4â€“B1: a pilot study. <i>BMC Cancer</i> , 2021, 21, 1169.	1.1	2
17	Simple low-cost approaches to semantic segmentation in radiation therapy planning for prostate cancer using deep learning with non-contrast planning CT images. <i>Physica Medica</i> , 2020, 78, 93-100.	0.4	17
18	Clinical impact of radiofrequency ablation and stereotactic body radiation therapy for colorectal liver metastasis as local therapies for elderly, vulnerable patients. <i>JGH Open</i> , 2020, 4, 722-728.	0.7	4

#	ARTICLE	IF	CITATIONS
19	A Multi-Institutional Retrospective Study of Repeated Stereotactic Body Radiation Therapy for Intrahepatic Recurrent Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1265-1275.	0.4	22
20	Methodological concerns for investigating the effects of mid-treatment break of stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC). <i>Radiotherapy and Oncology</i> , 2020, 147, 234.	0.3	1
21	Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies. <i>Acta Oncol³gica</i> , 2020, 59, 888-894.	0.8	10
22	Efficacy evaluation of 2D, 3D U-Net semantic segmentation and atlas-based segmentation of normal lungs excluding the trachea and main bronchi. <i>Journal of Radiation Research</i> , 2020, 61, 257-264.	0.8	49
23	Stereotactic body radiotherapy for primary non-small cell lung cancer patients with clinical T3-4N0M0 (UICC 8th edition): outcomes and patterns of failure. <i>Journal of Radiation Research</i> , 2019, 60, 639-649.	0.8	6
24	Stereotactic body radiotherapy for patients with non-small-cell lung cancer using RapidArc delivery and a steep dose gradient: prescription of 60% isodose line of maximum dose fitting to the planning target volume. <i>Journal of Radiation Research</i> , 2019, 60, 364-370.	0.8	7
25	Pleural contact decreases survival in clinical T1N0M0 lung cancer patients undergoing SBRT. <i>Radiotherapy and Oncology</i> , 2019, 134, 191-198.	0.3	5
26	Radiotherapy for Hepatocellular Carcinoma Results in Comparable Survival to Radiofrequency Ablation: A Propensity Score Analysis. <i>Hepatology</i> , 2019, 69, 2533-2545.	3.6	115
27	Are Head-to-Head Comparisons Between Radiofrequency Ablation and Stereotactic Body Radiotherapy Really Necessary for Localized Hepatocellular Carcinoma?. <i>Journal of Clinical Oncology</i> , 2018, 36, 2563-2564.	0.8	9
28	Stereotactic body radiotherapy for operable early-stage non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 109, 62-67.	0.9	26
29	Stereotactic body radiotherapy for lung cancer patients with idiopathic interstitial pneumonias. <i>Radiotherapy and Oncology</i> , 2017, 125, 310-316.	0.3	13
30	Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation. <i>Cancer</i> , 2016, 122, 2041-2049.	2.0	160
31	Stereotactic body radiotherapy for T3 and T4N0M0 non-small cell lung cancer. <i>Journal of Radiation Research</i> , 2016, 57, 265-272.	0.8	12
32	Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83-100 Gy in five fractions. <i>Journal of Radiation Research</i> , 2016, 57, 400-405.	0.8	37
33	Stereotactic body radiotherapy for chronic obstructive pulmonary disease patients undergoing or eligible for long-term domiciliary oxygen therapy. <i>Journal of Radiation Research</i> , 2016, 57, 62-67.	0.8	10
34	Role of stereotactic body radiation therapy for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2014, 20, 3100.	1.4	69
35	Role of stereotactic body radiotherapy for oligometastasis from colorectal cancer. <i>World Journal of Gastroenterology</i> , 2014, 20, 4220.	1.4	53
36	Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome analysis in 185 patients. <i>Acta Oncol³gica</i> , 2014, 53, 399-404.	0.8	222

#	ARTICLE	IF	CITATIONS
37	Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1370-1376.	0.5	50
38	Feasibility study of stereotactic body radiotherapy for peripheral lung tumors with a maximum dose of 100 Gy in five fractions and a heterogeneous dose distribution in the planning target volume. <i>Journal of Radiation Research</i> , 2014, 55, 988-995.	0.8	13
39	Threshold Doses for Focal Liver Reaction After Stereotactic Ablative Body Radiation Therapy for Small Hepatocellular Carcinoma Depend on Liver Function: Evaluation on Magnetic Resonance Imaging With Gd-EOB-DTPA. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 306-311.	0.4	64
40	Stereotactic ablative body radiation therapy with dynamic conformal multiple arc therapy for liver tumors: Optimal isodose line fitting to the planning target volume. <i>Practical Radiation Oncology</i> , 2014, 4, e7-e13.	1.1	7
41	Stereotactic ablative body radiotherapy for previously untreated solitary hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 372-379.	1.4	74
42	Subclinical interstitial lung disease: Is it a risk factor for fatal radiation pneumonitis following stereotactic body radiotherapy?. <i>Lung Cancer</i> , 2014, 83, 112.	0.9	15
43	Stereotactic Ablative Body Radiation Therapy for Octogenarians With Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 257-263.	0.4	66
44	Acceptable Toxicity After Stereotactic Body Radiation Therapy for Liver Tumors Adjacent to the Central Biliary System. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 85, 1006-1011.	0.4	70
45	Evaluation for local failure by 18F-FDG PET/CT in comparison with CT findings after stereotactic body radiotherapy (SBRT) for localized non-small-cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 248-253.	0.9	62
46	Tumor Response on CT Following Hypofractionated Stereotactic Ablative Body Radiotherapy for Small Hypervascular Hepatocellular Carcinoma With Cirrhosis. <i>American Journal of Roentgenology</i> , 2013, 201, W812-W820.	1.0	36
47	Reassessment of Declines in Pulmonary Function 1 Year After Stereotactic Body Radiotherapy. <i>Chest</i> , 2013, 143, 130-137.	0.4	42
48	Multiple myeloma relapse in the irradiated liver: involvement of hepatocyte growth factor akin to that after hepatocyte transplantation. <i>Journal of Radiotherapy in Practice</i> , 2012, 11, 271-273.	0.2	0
49	Severe COPD Is Correlated With Mild Radiation Pneumonitis Following Stereotactic Body Radiotherapy. <i>Chest</i> , 2012, 141, 858-866.	0.4	74
50	Analysis of suitable prescribed isodose line fitting to planning target volume in stereotactic body radiotherapy using dynamic conformal multiple arc therapy. <i>Practical Radiation Oncology</i> , 2012, 2, 46-53.	1.1	27
51	Acute Exacerbation of Usual Interstitial Pneumonia After Resection of Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2012, 93, 937-943.	0.7	48
52	Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. <i>Radiotherapy and Oncology</i> , 2011, 101, 255-259.	0.3	142
53	The maximum standardized uptake value (SUVmax) on FDG-PET is a strong predictor of local recurrence for localized non-small-cell lung cancer after stereotactic body radiotherapy (SBRT). <i>Radiotherapy and Oncology</i> , 2011, 101, 291-297.	0.3	93
54	Stereotactic Body Radiotherapy (SBRT) for Operable Stage I Non-Small-Cell Lung Cancer: Can SBRT Be Comparable to Surgery?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1352-1358.	0.4	561

#	ARTICLE	IF	CITATIONS
55	Early Graphical Appearance of Radiation Pneumonitis Correlates With the Severity of Radiation Pneumonitis After Stereotactic Body Radiotherapy (SBRT) in Patients With Lung Tumors. International Journal of Radiation Oncology Biology Physics, 2010, 77, 685-690.	0.4	53
56	Stereotactic Body Radiotherapy for Primary Lung Cancer at a Dose of 50 Gy Total in Five Fractions to the Periphery of the Planning Target Volume Calculated Using a Superposition Algorithm. International Journal of Radiation Oncology Biology Physics, 2009, 73, 442-448.	0.4	110
57	Dose Distribution Analysis in Stereotactic Body Radiotherapy Using Dynamic Conformal Multiple Arc Therapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 363-369.	0.4	56
58	Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiation Medicine, 2008, 26, 504-507.	0.8	58
59	Hypofractionated stereotactic radiotherapy with and without transarterial chemoembolization for small hepatocellular carcinoma not eligible for other ablation therapies: Preliminary results for efficacy and toxicity. Hepatology Research, 2008, 38, 60-69.	1.8	59
60	Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study. Journal of Thoracic Oncology, 2007, 2, S94-S100.	0.5	882
61	Small Lung Tumors: Long-Scan-Time CT for Planning of Hypofractionated Stereotactic Radiation Therapy—Initial Findings. Radiology, 2005, 237, 295-300.	3.6	43